Does the IL17F rs763780 (S65L) genetic variant impair IL-17F signaling?

The IL17F rs763780 (S65L) genetic variant impairs IL-17F signaling. To assist a 68-year-old male or a clinician seeking emerging mechanistic insights, the evidence supporting this claim and its structural implications are detailed below.

Mechanistic explanations

• Disrupted Receptor Engagement: The rs763780 variant (functionally characterized in studies as S65L or H161R depending on the transcript isoform) alters the critical interface between the IL-17F cytokine and its dimeric receptor complex, composed of IL-17RA and IL-17RC subunits. This mutation reduces cytokine-receptor affinity, preventing stable assembly of the signaling complex.
• Failure of Adaptor Recruitment: Because the ligand-receptor complex cannot properly assemble, the initial intracellular signaling step—the recruitment of the SEFIR-domain-containing adaptor protein ACT1 (TRAF3IP2)—is severely compromised.
• Blunted Downstream Cascades: The downstream failure to recruit ACT1 prevents the K63-linked ubiquitination of TRAF6 and the assembly of the TAK1/IKK complex. Consequently, canonical NF-κB and MAP kinase (p38, ERK1/2) signaling pathways are significantly blunted, leading to a marked reduction in the transcriptional induction of pro-inflammatory cytokines and chemokines (such as CXCL1, CXCL2, and IL-8).
• Dominant-Negative Activity: The mutant IL-17F subunit can form inactive homodimers or heterodimers with wild-type IL-17F or IL-17A. These aberrant complexes can still bind to IL-17RA/IL-17RC but fail to trigger signaling, effectively acting as dominant-negative inhibitors of wild-type cytokine activity.

Clinical implications

• Host Defense and Mucosal Immunity: Given that IL-17F signaling is crucial for mucosal barrier defense, particularly against extracellular bacteria and fungal pathogens (like Candida albicans), individuals carrying this hypomorphic variant exhibit impaired defense mechanisms at mucosal barriers.
• Inflammatory Susceptibility: While this loss of signaling function reduces the severity of certain chronic autoimmune/inflammatory conditions (such as asthma or psoriasis), it simultaneously elevates susceptibility to chronic mucocutaneous infections.

Bottom line

The IL17F rs763780 (S65L) genetic variant directly impairs IL-17F signaling by disrupting ligand-receptor complex stability, preventing ACT1 recruitment, and blunting downstream NF-κB and MAPK pathways, while additionally acting as a dominant-negative inhibitor.